Patents Assigned to Leptos Biomedical, Inc.
  • Publication number: 20100168820
    Abstract: Methods, Implantable Pulse Generators (IPGs), and systems for stimulating a sympathetic nervous system nerve including automatically increasing the maximum stimulation current intensity over time. Some IPGS increase the current stimulation current maximum upon passage of an elapsed time or occurrence of a time of day. The current stimulation current maximum is the actual stimulation current in some methods and is a ramp maximum in other methods. The patient may interact with the IPG to indicate discomfort, resulting in a decrease in the current stimulation current maximum. In some methods, after receiving too many patient indications of discomfort, stimulation is stopped by the IPG.
    Type: Application
    Filed: December 2, 2009
    Publication date: July 1, 2010
    Applicant: LEPTOS BIOMEDICAL INC.
    Inventors: Jeremy Maniak, Ralph Cardinal, Hans Neisz, Jason John Skubitz, Henry DeMorett
  • Publication number: 20100106207
    Abstract: A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight loss drug.
    Type: Application
    Filed: October 23, 2009
    Publication date: April 29, 2010
    Applicant: Leptos Biomedical, Inc.
    Inventor: John D. Dobak, III
  • Patent number: 7702386
    Abstract: The disclosure provides a description of a tissue modulation device, for treating at least one of obesity, metabolic syndrome, and Type 2 diabetes in a patient. In some embodiments, the device includes a storage module having computer-readable instructions for delivering an electrical stimulation pattern to a splanchnic nerve of the patient. The stimulation pattern includes at least one on-time. The on-time includes at least one of a suprathreshold period and a subthreshold period. The splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve. The pattern is effective to ameliorate at least one attendant condition of obesity, metabolic syndrome, and Type 2 diabetes in the patient. The attendant condition includes dyslipidemia, hypertension, hyperinsulinemia, hyperglycemia, and/or insulin resistance.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: April 20, 2010
    Assignee: Leptos Biomedical, Inc.
    Inventors: John D. Dobak, Hans Neisz
  • Patent number: 7689277
    Abstract: Systems and methods are described for treating metabolic syndrome and/or Type 2 diabetes, and/or one or more of their attendant conditions, by neural stimulation. In one embodiment, an implantable pulse generator is electrically coupled to a peripheral nerve, such as the splanchnic nerve. Neural stimulation configured to either block transmission or stimulate transmission of the peripheral nerve may be used to treat metabolic syndrome and Type 2 diabetes.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: March 30, 2010
    Assignee: Leptos Biomedical, Inc.
    Inventor: John D. Dobak, III
  • Patent number: 7689276
    Abstract: A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and/or duty cycle variance can produce therapeutic benefits.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: March 30, 2010
    Assignee: Leptos Biomedical, Inc.
    Inventor: John D. Dobak
  • Patent number: 7623924
    Abstract: Methods and devices for electrically stimulating nerves and organs to induce and modulate the production of hormones according to desired hormone production patterns and hormone level patterns to treat gynecological conditions. Such methods and devices may be used to treat or alleviate the symptoms of menopause. In addition, such methods and devices may be used for birth control.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: November 24, 2009
    Assignee: Leptos Biomedical, Inc.
    Inventor: Hugh Louis Narciso, Jr.
  • Patent number: 7551964
    Abstract: A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: June 23, 2009
    Assignee: Leptos Biomedical, Inc.
    Inventor: John D. Dobak, III
  • Publication number: 20080033511
    Abstract: Described are apparatus and methods for electrically modulating a nerve in a mammal. An electrical signal that includes a signal intensity pattern and a signal frequency pattern is delivered to a nerve. The combination of the signal intensity pattern and the signal frequency pattern is effective to result in weight loss, fat loss, and/or lean-mass gain, in a mammal. In some embodiments the nerve is modulated in response to a physiological parameter. In some embodiments, the physiological parameter is measured by a sensor.
    Type: Application
    Filed: June 11, 2007
    Publication date: February 7, 2008
    Applicant: Leptos Biomedical, Inc.
    Inventor: John Dobak
  • Publication number: 20070225768
    Abstract: A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
    Type: Application
    Filed: May 17, 2007
    Publication date: September 27, 2007
    Applicant: Leptos Biomedical, Inc.
    Inventor: John Dobak
  • Publication number: 20070219596
    Abstract: A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
    Type: Application
    Filed: May 17, 2007
    Publication date: September 20, 2007
    Applicant: Leptos Biomedical, Inc.
    Inventor: John Dobak
  • Patent number: 7239912
    Abstract: A method for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: July 3, 2007
    Assignee: Leptos Biomedical, Inc.
    Inventor: John D. Dobak, III
  • Patent number: 7236822
    Abstract: A method for the treatment of obesity or other disorders, by wireless electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by wirelessly stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using a wireless electrode inductively coupled with a radiofrequency field. The source of radiofrequency energy may be internal or external to the patient. This nerve activation can result in reduced food intake and increased energy expenditure.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: June 26, 2007
    Assignee: Leptos Biomedical, Inc.
    Inventor: John D. Dobak, III